Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA5A | P35218 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 8/20 | 0.53 |
| ▸ | GAA | P10253 | 8/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL667827 | 0.89 | CA2 (0.67) | CA2CA5AMAPTGAAGLA | |
| SCHEMBL28916359 | 0.82 | CA2 (0.60) | CA2CA5AMAPTGAAGLA | |
| SCHEMBL28049803 | 0.78 | CA2 (0.56) | CA2CA5AMAPTGAAGLA | |
| SCHEMBL7043304 | 0.78 | GAA (0.64) | CA2CA5AMAPTGAAGLA | |
| SCHEMBL1520890 | 0.78 | GAA (0.61) | CA2CA5AMAPTGAAGLA | |
| SCHEMBL10514852 | 0.78 | ALDH1A1 (0.47) | MAPTGAAALDH1A1ALOX12HPGD | |
| SCHEMBL6156958 | 0.78 | ALDH1A1 (0.63) | CA2MAPTGAAALDH1A1ALOX12 | |
| SCHEMBL6680813 | 0.78 | CA2 (0.56) | CA2CA5AMAPTGAAGLA | |
| SCHEMBL145719 | 0.77 | IDO1 (0.63) | CA2MAPTGAAALDH1A1ALOX12 | |
| SCHEMBL163118 | 0.77 | ALDH1A1 (0.61) | CA2CA5AMAPTGAAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005092873-A2 | THIADIAZOLES FOR TREATMENT OF CANCER OR NEUROLOGICAL DISEASE | UNIWERSYTET MARII CURIE SKLODOWSKIEJ (PL) | 2005-10-06 | — | — | WO | claimed |
| WO-2024124297-A1 | ANTI-CANCER COMPOUNDS AND USES THEREOF | GRIFFITH UNIVERSITY (AU) | 2024-06-20 | — | — | WO | disclosed |
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2023-07-25 | — | — | US | disclosed |
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2023-07-25 | — | — | US | disclosed |
| US-20220048909-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-02-17 | — | — | US | disclosed |
| CN-105111192-B | Triazole Mannich base class compound and its preparation and application containing trifluoromethyl and piperazine | 南开大学 | 2019-03-05 | — | — | CN | disclosed |
| CN-106854213-B | Lavo-ofloxacin aldehyde contracting 4- arylamino thiourea derivatives and its preparation method and application | 郑州工业应用技术学院 | 2018-11-23 | — | — | CN | disclosed |
| US-10017496-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20180148447-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE | IGNYTA, INC. (US) | 2018-05-31 | — | — | US | disclosed |
| CN-108047201-A | Uracil derivative as AXL and c-MET kinase inhibitors | 亚尼塔公司 | 2018-05-18 | — | — | CN | disclosed |
| WO-2015100117-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE | CEPHALON, INC. (US) | 2015-07-02 | — | — | WO | disclosed |
| US-9029538-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2780338-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | Cephalon, Inc. (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| CN-103958497-A | Uracil derivatives as AXL and c-MET kinase inhibitors | CEPHALON INC | 2014-07-30 | — | — | CN | disclosed |
| WO-2013074633-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2012033601-A1 | THIOSEMICARBAZONES WITH MDR1 - INVERSE ACTIVITY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2012-03-15 | — | — | WO | disclosed |
| EP-2240175-A2 | COMPOUNDS WITH MDR1-INVERSE ACTIVITY | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009102433-A2 | COMPOUNDS WITH MDR1-INVERSE ACTIVITY | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-08-20 | — | — | WO | disclosed |
| WO-2005092873-A2 | THIADIAZOLES FOR TREATMENT OF CANCER OR NEUROLOGICAL DISEASE | UNIWERSYTET MARII CURIE SKLODOWSKIEJ (PL) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | REN, NR3C2, PKD1 | CA2 1093/4885CA5A 1375/4885MAPT 4450/4885 |
| US-20180148447-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE | AXL, FLT3, ERBB2 | CA2 2357/4885CA5A 1787/4885MAPT 2412/4885 |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, BRAF | CA2 2474/4885CA5A 3576/4885MAPT 2880/4885 |
| US-20220048909-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | REN, NR3C2, PKD1 | CA2 1093/4885CA5A 1375/4885MAPT 4450/4885 |
| US-10017496-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | AXL, RET, FLT3 | CA2 2372/4885CA5A 3485/4885MAPT 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.